Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Reata Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RETA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Reata Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Why Avantor Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
July 28, 2023
Gainers Unique Fabricating, Inc. (NYSE: UFAB) shares jumped 113% to $0.4605 after gaining 12% on Thursday.
Via
Benzinga
Biogen (NASDAQ: BIIB) Acquires Reata (NASDAQ: RETA) to Boost its Neurological Therapeutics Portfolio, Including SKYCLARYS®
July 28, 2023
Reata's Acquisition to Propel Biogen's Growth Strategy Biogen Inc. (NASDAQ: BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have announced a
Via
Spotlight Growth
Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals
↗
July 28, 2023
Via
Benzinga
Expert Ratings for Reata Pharmaceuticals
↗
July 24, 2023
Via
Benzinga
Reata Pharmaceuticals Inc. (NASDAQ: RETA) is a Stock Spotlight on 7/17
July 17, 2023
Via
Investor Brand Network
Dow Surges 250 Points; Exxon Mobil Earnings Miss Expectations
↗
July 28, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 250 points on Friday. The Dow traded up 0.72% to 35,535.23 while the NASDAQ rose 1.89% to 14,316.53. The S&P 500,...
Via
Benzinga
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
↗
July 28, 2023
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of
Via
Benzinga
Skechers, Chart Industries, Roku, Beazer Homes And Other Big Stocks Moving Higher On Friday
↗
July 28, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) rose...
Via
Benzinga
What 5 Analyst Ratings Have To Say About Reata Pharmaceuticals
↗
June 28, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Reata Pharmaceuticals
↗
June 12, 2023
Via
Benzinga
Why Is QuantumScape (QS) Stock Up 10% Today?
↗
July 28, 2023
QuantumScape (QS) stock is continuing to rally on Friday following an update from its latest earnings report and EV battery plans.
Via
InvestorPlace
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
↗
July 28, 2023
Reata Pharmaceuticals (RETA) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (BIIB).
Via
InvestorPlace
Nasdaq Jumps 200 Points; Procter & Gamble Posts Upbeat Earnings
↗
July 28, 2023
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.39% to 35,419.43 while the NASDAQ rose...
Via
Benzinga
Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals
↗
July 28, 2023
Reata stock surged more than 50% on the news.
Via
Investor's Business Daily
Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B
↗
July 28, 2023
Biogen Inc (NASDAQ: BIIB) has agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
July 28, 2023
Via
Benzinga
RETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to Shareholders
July 28, 2023
From
Halper Sadeh LLC
Via
Business Wire
Biogen to Acquire Reata Pharmaceuticals
July 28, 2023
From
Biogen Inc.
Via
GlobeNewswire
3 Top Biotech Stocks Defying the Bear Market
↗
July 13, 2023
Each has the potential to dramatically outperform the market.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
↗
July 06, 2023
Via
Benzinga
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review
↗
June 30, 2023
Major indexes rebounded strongly and many stocks flashed buy signals.
Via
Investor's Business Daily
Reata Surges 16% Over Three Days; CEO Reflects On The Tricky Path To Launch A First-Ever Drug
↗
June 29, 2023
The company can now launch its Friedreich's ataxia treatment, Skyclarys.
Via
Investor's Business Daily
Reata Nears Breakout After Snagging FDA Blessing To Launch Its Friedreich's Ataxia Drug
↗
June 28, 2023
The company has now launched its treatment for Friedreich's ataxia, despite numerous obstacles.
Via
Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
June 28, 2023
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on!
Via
InvestorPlace
Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia
June 27, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Reata, DLocal, Comerica, and Advance Auto Parts and Encourages Investors to Contact the Firm
June 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Top 1% Biotech Stock Reata Pharmaceuticals Faces Another Hurdle
↗
June 16, 2023
Reata Pharmaceuticals took another step toward launching its highly anticipated drug, Skyclarys.
Via
Investor's Business Daily
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement
June 15, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
June 15, 2023
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.
Via
Benzinga
Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer
June 13, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
